Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Average Price Target of $13.86

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has earned an average recommendation of “Hold” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $13.86.

A number of research firms have recently issued reports on BCYC. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Zacks Research cut shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Finally, Needham & Company LLC decreased their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 30th.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $3.55 on Thursday. The stock has a market capitalization of $248.46 million, a price-to-earnings ratio of -1.30 and a beta of 1.68. The stock’s 50 day moving average price is $3.87 and its two-hundred day moving average price is $4.21. Bicycle Therapeutics has a 52 week low of $3.33 and a 52 week high of $9.08.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. On average, equities research analysts forecast that Bicycle Therapeutics will post -2.26 EPS for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in shares of Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after buying an additional 412,700 shares during the last quarter. Rangeley Capital LLC boosted its holdings in shares of Bicycle Therapeutics by 76.0% during the 1st quarter. Rangeley Capital LLC now owns 232,260 shares of the company’s stock worth $1,078,000 after buying an additional 100,260 shares during the period. Marquette Asset Management LLC bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth about $309,000. ADAR1 Capital Management LLC acquired a new position in Bicycle Therapeutics in the 1st quarter valued at about $331,000. Finally, Principal Financial Group Inc. grew its stake in Bicycle Therapeutics by 2.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock valued at $5,450,000 after buying an additional 26,353 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.